Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations

US10287587B2 · kind B2 · utility

Assignee

• The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. · US

Inventors

• Shiv Srivastava · Potomac, US
• Albert Dobi · Columbia, US
• Taduru Sreenath · Germantown, US
• Gyorgy Petrovics · Bethesda, US
• Chen Sun · Beijing, CN

Key dates

• Filing date: Aug 22, 2013
• Grant date: May 14, 2019
• Expiry date: Jul 25, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/16
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure describes alterations in ERG gene expression. ERG isoforms and promoter sequence of the ERG gene that are involved in, or associated with, prostate cancer are provided. The disclosure further provides therapeutic compositions and methods of detecting, diagnosing, prognosing, and treating prostate cancer, including biomarkers for detecting the expression of two or more of the following genes: PSA/KLK3, PMEPA1, NKX3.1, ODC1, AMD1, and ERG.